Does Dr. HIND ABD ELGADIR have financial conflicts of interest?

Dr. HIND ABD ELGADIR (MD) has received a total of $512 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $512 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. HIND ABD ELGADIR?

According to CMS Open Payments data, Dr. HIND ABD ELGADIR received funding from GENZYME CORPORATION ($219), NOVO NORDISK ($144), and SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US ($130).

Does Dr. HIND ABD ELGADIR receive research grants or speaking fees?

Dr. HIND ABD ELGADIR has received $512 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. HIND ABD ELGADIR

MDReal-Time Hydrated

Specialty: Internal Medicine, Critical Care Medicine

Practice Location: KANSAS CITY, KS 66160

NPI Number: 1992386015

LIFETIME INDUSTRY VALUE

$512

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ABD ELGADIR is a verified Internal Medicine, Critical Care Medicine practitioner based in KANSAS CITY, KS.

Between 2021 and 2025, Dr. ABD ELGADIR had an overall industry promotional and research financial footprint of $512 as recorded in the federal CMS Open Payments database.

$512 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABD ELGADIR's primary funding source is GENZYME CORPORATION, which accounts for $219 (representing 42.8% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GENZYME CORPORATION

Rank 1

$219

42.8%

NOVO NORDISK

Rank 2

$144

28.2%

SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US

Rank 3

$130

25.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.